ENO1 and pulmonary fibrosis: In brief, targeting ENO1 by our proprietary antibody HL217 ameliorates bleomycin-induced pulmonary fibrosis in vivo as evidenced by the attenuation of fibrosis (i.e., collagen deposition in lungs), TGF-β reduction in BALF, and immune cells infiltration in lungs.